Biogen (BIIB) Sale Dependent on Value of Aducanumab - BMO Capital
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/11/2026
Go back to Biogen (BIIB) Sale Dependent on Value of Aducanumab - BMO Capital
August 3, 2016 7:38 AM EDT
Leerink Partners analyst Geoffrey Porges weighed in on Biogen (NASDAQ: BIIB) amid reports Tuesday that the company is in talks with Merck and Allergan on a potential takeout.
Porges said while they have no information to confirm the suggestions that Merck (MP) and Allergan (OP) are among the potential suitors, it certainly makes sense to us.
"In our recent notes we have suggested... More
August 3, 2016 7:17 AM EDT
Baird analyst Brian Skorney weighed in on Biogen (NASDAQ: BIIB) amid reports Tuesday that the company is in talks with Merck and Allergan on a potential takeout.
Skorney commented, "Though we are not surprised that takeout discussions are taking place, we question the... More
August 2, 2016 3:41 PM EDT
Biogen (NASDAQ: BIIB) could be worth $375-$475/share in a takeover RBC Capital's Michael Yee said following reports from the WSJ the company has attracted takeover... More
August 2, 2016 2:43 PM EDT
(Updated - August 2, 2016 2:49 PM EDT)
Biogen (Nasdaq: BIIB) attracted takeover interest from Allergan (NYSE: AGN) and Merck (NYSE: MRK), according to Dow Jones, citing sources. The two companies reportedly... More
